BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2027

Conditions
Sickle Cell Disease
Interventions
BIOLOGICAL

BEAM-101

Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan

Trial Locations (20)

10032

RECRUITING

Columbia University Irving Medical Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

29425

RECRUITING

Medical University of South Carolina, Charleston

30329

RECRUITING

Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital, Atlanta

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

37203

RECRUITING

The Children's Hospital at TriStar Centennial, Nashville

38105

RECRUITING

St Jude Children's Research Hospital, Memphis

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

44195

RECRUITING

The Cleveland Clinic Foundation, Cleveland

48202

RECRUITING

Henry Ford Cancer Center, Detroit

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

55455

RECRUITING

University of Minnesota, Minneapolis

63110

RECRUITING

Washington University School of Medicine in St. Louis, St Louis

85016

RECRUITING

Phoenix Children's Hospital, Phoenix

94304

RECRUITING

Lucile Packard Children's Hospital at Standford, Palo Alto

33136-1005

RECRUITING

University of Miami, Miami

02215

RECRUITING

Boston Children's Hospital, Boston

07601

RECRUITING

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Beam Therapeutics Inc.

INDUSTRY